Combined Chelation Therapy with Deferasirox and Deferoxamine in Thalassemia

Iron overload is the primary cause of mortality and morbidity in thalassemia major despite advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and efficacy of combined therapy with deferasirox (DFX, 20-30 mg/kg daily) and deferoxamine (DFO, 35-50 mg/kg on 3-7 da...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lal, Ashutosh, Porter, John, Sweeters, Nancy, Ng, Vivian, Evans, Patricia, Neumayr, Lynne, Kurio, Gregory, Harmatz, Paul, Vichinsky, Elliott
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3592978/
https://ncbi.nlm.nih.gov/pubmed/23151373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcmd.2012.10.006
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak